Top Clinical Trials companies in Switzerland by Current Liabilities
This ranking features the top 3 Clinical Trials companies in Switzerland ranked by Current Liabilities, totalling a Current Liabilities of USD 94.76 M, for January 15, 2025.
Switzerland
Clinical Trials
Current Liabilities
# |
Name |
Current Liabilities |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
USD 67.67 M
|
Dec. 31, 2023 | USD 1.71 | -0.58% |
|
Switzerland |
|
| 2 |
USD 17.12 M
|
Dec. 31, 2023 | USD 5.48 | 3.60% |
|
Switzerland |
|
| 3 |
USD 9.97 M
|
Dec. 31, 2023 | USD 46.50 | 2.74% |
|
Switzerland |
Frequently Asked Questions
-
Which Clinical Trials company in Switzerland has the highest Current Liabilities ?
The Clinical Trials company in Switzerland with the highest Current Liabilities is ADC Therapeutics SA (NYSE: ADCT) at USD 67.67 M.
-
Which Clinical Trials company in Switzerland has the lowest Current Liabilities ?
The Clinical Trials company in Switzerland with the lowest Current Liabilities is MoonLake Immunotherapeutics (NasdaqCM: MLTX) at USD 9.97 M.
-
What are the top 10 Clinical Trials companies in Switzerland by Current Liabilities ?
The top 10 Clinical Trials companies in Switzerland by Current Liabilities are ADC Therapeutics SA, Molecular Partners AG and MoonLake Immunotherapeutics.
-
What are the bottom 10 Clinical Trials companies in Switzerland by Current Liabilities ?
The bottom 10 Clinical Trials companies in Switzerland by Current Liabilities are MoonLake Immunotherapeutics, Molecular Partners AG and ADC Therapeutics SA.